Toceranib (Standard)
Toceranib (Standard) is the analytical standard of Toceranib (HY-10330). This product is intended for research and analytical applications. Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 356068-94-5
- Formule: C22H25FN4O2
- Masse moléculaire:396.46
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-10330
ToceranibRTK Inhibitor -
HY-10255A
SunitinibMulti-targeted RTK Inhibitor -
HY-50904
NintedanibPDGFR/VEGFR/FGFR Inhibitor -
HY-10201
SorafenibMultikinase Inhibitor -
HY-13223
CrenolanibFLT3 Inhibitor -
HY-10208
PazopanibVEGFR Inhibitor -
HY-15463
ImatinibTyrosine Kinases Inhibitor -
HY-10065
AxitinibTyrosine Kinase Inhibitor -
HY-10255AR
Sunitinib (Standard)Multi-targeted RTK Inhibitor -
HY-12050
CP-673451PDGFR Inhibitor -
HY-11106
Nintedanib esylatePDGFR/VEGFR/FGFR Inhibitor -
HY-15506
TAK-593VEGFR/PDGFR Inhibitor
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 356068-94-5
-
Masse moléculaire 396.46
-
Formule C22H25FN4O2
-
SMILES
O=C(NCCN1CCCC1)C2=C(NC(/C=C3C(NC4=C\3C=C(C=C4)F)=O)=C2C)C
-
Synonyms
SU11654 (Standard); PHA 291639E (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. London CA, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9(7):2755-68. [Content Brief]
[2]. Halsey CH, et al. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia?) in canine mast cell tumor. BMC Vet Res. 2014 May 6;10:105. [Content Brief]
[3]. Mitchell L, et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr;26(2):355-62. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Toceranib (Standard) Related Classifications
HY-10330R Related Classifications
Powered by Bioz